AMW gets follow-on funding
AMW has secured follow-on financing to advance the development and marketing process for its drug delivery systems. BayBG Bayerische Beteiligungsgesellschaft, UnternehmerTUM Fund and IBG Beteiligungsgesellschaft are joining existing investors in the round. AMW produces active ingredient implants and transdermal systems in the areas of oncology, pain therapy and neurology.
9 September 2014•4 mins read
